Cardiac disease in mucopolysaccharidosis type I attributed to catecholaminergic and hemodynamic deficiencies

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 1, 2011, Pages

  Palpant, Nathan J ^a   Bedada, Fikru B ^a   Peacock, Brandon ^a   Blazar, Bruce R ^a   Metzger, Joseph M ^a   Tolar, Jakub ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Cardiomyopathy; Hurler syndrome; Phosphorylation

Indexed keywords

DOBUTAMINE;

ADRENERGIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART OUTPUT; HURLER SYNDROME; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADRENERGIC BETA-1 RECEPTOR AGONISTS; ANIMALS; ANTHRACENES; BLOTTING, WESTERN; DOBUTAMINE; HEART; HEART DISEASES; HEMODYNAMICS; LINEAR MODELS; MICE; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS I; MYOCARDIUM; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78651341103     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00774.2010     Document Type: Article

References (34)

1. Baurand A, Zelarayan L, Betney R, Gehrke C, Dunger S, Noack C, Busjahn A, Huelsken J, Taketo MM, Birchmeier W, Dietz R, Bergmann MW. Beta-catenin downregulation is required for adaptive cardiac remodeling. Circ Res 100: 1353-1362, 2007.
2. Beesley CE, Meaney CA, Greenland G, Adams V, Vellodi A, Young EP, Winchester BG. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 109: 503-511, 2001.
3. Boelens JJ, Rocha V, Aldenhoven M, Wynn R, O'Meara A, Michel G, Ionescu I, Parikh S, Prasad VK, Szabolcs P, Escolar M, Gluckman E, Cavazzana-Calvo M, Kurtzberg J. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant 15: 618-625, 2009.
4. Braunlin E, Mackey-Bojack S, Panoskaltsis-Mortari A, Berry JM, McElmurry RT, Riddle M, Sun LY, Clarke LA, Tolar J, Blazar BR. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome. Pediatr Res 59: 27-32, 2006.
5. Braunlin EA, Berry JM, Whitley CB. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 98: 416-418, 2006.
6. Brodde OE. Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 374: 361-372, 2007.
7. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharm Sci 100: 323-337, 2006.
8. Clarke LA, Russell CS, Pownall S, Warrington CL, Borowski A, Dimmick JE, Toone J, Jirik FR. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet 6: 503-511, 1997.
9. Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders - clinical and echocardiographic findings in 64 patients. Eur J Pediatr 157: 534-538, 1998.
10. Dash R, Kadambi VJ, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW 2nd, Kranias EG. Interactions between phospholamban and β-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103: 889-896, 2001.
11. Day SM, Westfall MV, Fomicheva EV, Hoyer K, Yasuda S, La Cross NC, D'Alecy LG, Ingwall JS, Metzger JM. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat Med 12: 181-189, 2006.
12. Frank K, Kranias EG. Phospholamban and cardiac contractility. Ann Med 32: 572-578, 2000.
13. Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol 27: 849-856, 1995.
14. Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, James DC, Lucas CF, Rogers TR, Benson PF, Tansley LR, Patrick AD, Mossman J, Young EP. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2: 709-712, 1981.
15. Jordan MC, Zheng Y, Ryazantsev S, Rozengurt N, Roos KP, Neufeld EF. Cardiac manifestations in the mouse model of mucopolysaccharidosis I. Mol Genet Metab 86: 233-243, 2005.
16. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Doroshow R, Walot I, Hoft R, Neufeld EF. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344: 182-188, 2001.
17. Layland J, Solaro RJ, Shah AM. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66: 12-21, 2005.
18. Liu Y, Xu L, Hennig AK, Kovacs A, Fu A, Chung S, Lee D, Wang B, Herati RS, Mosinger Ogilvie J, Cai SR, Parker Ponder K. Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol Ther 11: 35-47, 2005.
19. Matte U, Yogalingam G, Brooks D, Leistner S, Schwartz I, Lima L, Norato DY, Brum JM, Beesley C, Winchester B, Giugliani R, Hopwood JJ. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab 78: 37-43, 2003.
20. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: The Metabolic Basis of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, and Valle D. New York: McGraw Hill, 1997, p. 2465-2494.
21. Palpant NJ, D'Alecy LG, Metzger JM. Single histidine button in cardiac troponin I sustains heart performance in response to severe hypercapnic respiratory acidosis in vivo. FASEB J 23: 1529-1540, 2009.
22. Palpant NJ, Day SM, Herron TJ, Converso KL, Metzger JM. Single histidine-substituted cardiac troponin I confers protection from age-related systolic and diastolic dysfunction. Cardiovasc Res 80: 209-218, 2008.
23. Renteria VG, Ferrans VJ, Roberts WC. The heart in the Hurler syndrome: gross, histologic and ultrastructural observations in five necropsy cases. Am J Cardiol 38: 487-501, 1976.
24. Shull RM, Munger RJ, Spellacy E, Hall CW, Constantopoulos G, Neufeld EF. Canine alpha-L-iduronidase deficiency. A model of mucopolysaccharidosis I. Am J Pathol 109: 244-248, 1982.
25. Sleeper MM, Fornasari B, Ellinwood NM, Weil MA, Melniczek J, O'Malley TM, Sammarco CD, Xu L, Ponder KP, Haskins ME. Gene therapy ameliorates cardiovascular disease in dogs with mucopolysaccharidosis VII. Circulation 110: 815-820, 2004.
26. Sleeper MM, Kusiak CM, Shofer FS, O'Donnell P, Bryan C, Ponder KP, Haskins ME. Clinical characterization of cardiovascular abnormalities associated with feline mucopolysaccharidosis I and VI. J Inherit Metab Dis 31: 424-431, 2008.
27. Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, Allison-Thacker J, Wood S, Wenger DA, Rubinstein P, Hopwood JJ, Krivit W, Kurtzberg J. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350: 1960-1969, 2004.
28. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeysinghe S, Krawczak M, Cooper DN. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21: 577-581, 2003.
29. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262, 1999.
30. Tolar J, Grewal SS, Bjoraker KJ, Whitley CB, Shapiro EG, Charnas L, Orchard PJ. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant 41: 531-535, 2008. (Pubitemid 351472144)
31. Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, Metzger JM. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 15: 1086-1092, 2007.
32. 2+- sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res 57: 37-47, 2003.
33. Xiang Y, Kobilka BK. Myocyte adrenoceptor signaling pathways. Science 300: 1530-1532, 2003.
34. Zelarayan L, Gehrke C, Bergmann MW. Role of beta-catenin in adult cardiac remodeling. Cell Cycle 6: 2120-2126, 2007.